Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

Share this article
Share this article
WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has entered into a $15 million debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund").
"We are pleased to partner with Avenue Venture Fund and their team as we achieve some of the most significant milestones in our company's history. This non-dilutive funding will support validation testing of the first tankless iNO (inhaled nitric oxide) wearable device for home use," said Bill Athenson, Third Pole's CEO. "We appreciate Avenue's confidence in our late-stage FDA designated 'breakthrough' hospital and wearable platforms that deliver portable iNO therapies from hospital to home."

Related Keywords

Elizabeth Holmberg ,Venture Opportunities Fund ,Venture Fund ,Lp Avenue Venture Fund ,Capital Group ,Third Pole Therapeutics Inc ,Senior Portfolio Venture Fund ,Third Pole Therapeutics ,Avenue Venture Opportunities Fund ,Avenue Venture Fund ,Bill Athenson ,Third Pole ,Senior Portfolio Manager ,Board Chairman Bill ,Avenue Capital Group ,Pole Therapeutics ,Chief Financial Officer ,எலிசபெத் ஹோலம்பெர்க் ,துணிகர நிதி ,மூலதனம் குழு ,மூன்றாவது போலே சிகிச்சை இன்க் ,மூன்றாவது போலே சிகிச்சை ,மூன்றாவது போலே ,மூத்தவர் போர்ட்‌ஃபோலீயோ மேலாளர் ,பலகை தலைவர் ர சி து ,அவென்யூ மூலதனம் குழு ,போலே சிகிச்சை ,தலைமை நிதி அதிகாரி ,